Terry Dubrow's HealthRX starts selling six peptides
Also in this issue: LifeMD cuts its 2026 revenue outlook
Forwarded this? Get it weekday mornings.
Take. HealthRX, a national seller with a TV surgeon in its ads, prices BPC-157 at $129 a month on a yearly plan and $199 month to month. Peptide patients will quote those numbers back to you. Before your next peptide consult, put your price next to them and name what the difference buys.
HealthRX, a telehealth seller, lists all six peptides from HHS's draft compounding policy on its homepage: BPC-157, TB-500, MOTS-c, Epitalon, Semax nasal spray and KPV. Each needs a prescription after an online review. The page says a state-licensed 503A pharmacy makes them. The peptide offer runs $99 for the first month on a plan, then from $129 a month on a 12-month plan, or $199 month to month. Compounded semaglutide and tirzepatide are $39 for the first month.
Plastic surgeon Terry Dubrow fronts the launch. The company's launch release calls him a partner. The homepage calls him founder and chief medical officer. In the launch film he answers 23 questions while hooked up to a polygraph. "These are real medical treatments and they deserve real medical oversight," he says in the release. The same release says the HHS policy "is not FDA approval, and compounded medications are not FDA approved."
Enhanced has prescribed the same six peptides since Nov. 3. Hims & Hers says its peptide line starts this month.
HHS published the draft in the Federal Register last month. HHS would hold off enforcement against 503A pharmacies that compound the six peptides under its conditions. It approves no drug. Comments close today, Friday, Nov. 13. The American Medical Association voted Monday to urge HHS and FDA to rescind the policy.
Know a pharmacy or clinic owner setting peptide prices this month? Forward this to them. They can get ODR free every weekday morning.
Supply
Peptide sellers name no API makers
Every peptide on these menus starts as an active pharmaceutical ingredient, or API, the raw drug substance a pharmacy compounds from. HealthRX says a "state-licensed 503A pharmacy" makes its peptides. It names neither the pharmacy nor the API maker. Enhanced's launch release goes further. It says its APIs come from "FDA-registered, CGMP-compliant manufacturers" with certificates of analysis. It names no maker either. FDA checks claims like these. In a warning letter to Texas seller RonanRx last month, FDA said its records list no U.S.-registered maker of semaglutide or tirzepatide API for compounding. FDA said that made RonanRx's "American made" claim misleading.
We expect sourcing to be the next thing peptide sellers compete on, now that prices are public. A clinic whose pharmacy can name its API maker has an answer HealthRX's homepage doesn't give.
The Signal
Telehealth
LifeMD cuts its 2026 revenue outlook
LifeMD, a public virtual primary care and pharmacy company, reported third-quarter revenue of $45 million Thursday, down about 7% from a year earlier. CEO Justin Schreiber said in the results release that revenue came in below guidance. LifeMD now expects $188 million to $191 million for 2026, down from $206 million to $213 million. It cut selling and marketing 34% from the second quarter, to $19 million. Schreiber said cost per acquisition fell 32% from May to September while monthly media spend fell 45%. The 8-K also shows a $13 million Avenue Capital term loan closed Monday at the greater of prime plus 4.5% or 11.5%. LifeMD must keep trailing 12-month revenue of at least $150 million. Neither filing sizes the accounting corrections LifeMD flagged in its late-filing notice this week.
Telehealth
Join Luma lists compounded tirzepatide at $149 a month prepaid
Join Luma, a New York weight-loss telehealth brand, says its compounded tirzepatide costs $149 a month on a prepaid plan, per its release. New patients pay $447 up front for three months. That plan renews at $537. The release cites a magazine ranking that called Join Luma the cheapest of seven sellers. Separately, TelePep put compounded semaglutide back on its pricing page at $149 a month billed monthly. It listed $199 before the drug left the page earlier this month.
Everyone
Nebraska confirms it joined FTC suit against Hims & Hers
Nebraska's attorney general said Thursday the state joined the FTC's amended suit against Hims & Hers. Arizona, Utah, Florida, Ohio, Wisconsin and Los Angeles County have joined too. These are allegations.
Medspa
Boulevard's AI receptionist starts booking appointments on calls
Boulevard sells booking and payments software to spas and medspas. Its AI receptionist, Beau, can now book a new single-service appointment during the phone call, per Boulevard's changelog. If the client has a card on file, the booking happens on the call. If not, Beau texts a prefilled link and the client has 30 minutes to add a card. Before it shares or changes appointment details, it confirms who's calling. Clinical businesses check date of birth, with a one-time passcode as backup. The rollout runs in waves over the next week.
Wire
- DEA's special-registration rule for telemedicine prescribing is still under White House review on reginfo.gov. The 90-day mark is Monday, Nov. 23, with one 30-day extension allowed.
- Eagle Pharma Outsourcing, a 503B facility in Hoover, Ala., is recalling phenylephrine and oxytocin IV bags over sterility assurance, per FDA's enforcement report.
Optimized Daily Report is business news for clinic operators. Not medical, legal, or investment advice. Company claims are the company's.